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Does the Circadian Clock
Control Cell Cycle?
A variety of molecular, genomic and epidemiological
evidence has linked cell cycle regulation to circadian
rhythms. In a recent issue of Molecular Cell, Koeffler
and colleagues show that PER1 sensitizes human
cancer cells to ionizing radiation-induced apoptosis.
In addition, PER1 expression was found to be down-
regulated in human tumors, suggesting a tumor sup-
pressor role for the PER1 protein. The significance
of PERs, clocks, and cell cycle control is discussed.
It is well recognized that organisms sense and respond
to daily oscillations in light by altering their physiological
processes and activities. This cycling, know as the cir-
cadian rhythm, imparts a biological advantage by allow-
ing an organism to keep in step with its changing envi-
ronment. At the cellular level, these cycles correspond
to diurnal fluctuations in the availability of not only nutri-
ents and oxygen, but also to cell stressors and damag-
ing agents. Thus it seems logical that cell division would
be linked to circadian rhythms. In support of this idea,
transcriptome analysis has revealed that many impor-
tant cell cycle genes are regulated in a circadian fash-
ion. Such genes include MYC (G0/G1 transition), cyclin-
D1 (G1/S transition), and WEE1 (G2/M transition) (Fu
et al., 2002; Matsuo et al., 2003). These genes function
at important regulatory points of the cell cycle, suggest-
ing that the circadian oscillator may control various
points of cell division. If this idea is true, then it could
provide insight into human proliferative diseases such
as cancer.
In addition to the molecular and genomic support for
the idea of circadian regulation of the cell cycle, there is
epidemiological evidence for a relationship between
disruption of circadian regulation and cancer. In this
regard, an increased risk for breast cancer has been
reported among female night shift workers (Hansen,
2001). Similarly, patients with colorectal cancers who
exhibited normal daily rhythms had longer survival com-
pared to those with disrupted circadian rhythms (Mor-
mont et al., 2000). In addition, studies investigating the
timing and efficacy of cancer treatments (‘‘chronother-
apy’’) indicate that the status of the circadian oscillator
can influence cellular responses to genotoxic stress in-
duced during chemotherapy (Gorbacheva et al., 2005).
This influence is thought to have a metabolic compo-
nent, but may also involve a sensitivity of cancer cells
at particular times of the circadian day. Taken in sum,
there are indications from both in vitro and in vivo stud-
ies that support the connection between circadian
rhythms and cancer sensitivity.
Circadian oscillations in gene expression are reliant
upon a feedback loop of transcriptional activation and
repression. Central to this loop is the CLOCK/BMAL1(MOP3) heterodimer that acts in the positive arm of
the circadian cycle by transactivating clock-controlled
genes (CCGs) such as the Period (PER1-3) and the
Cryptochrome (CRY1-2) genes. The products of the
PER and CRY genes play a role in the negative arm of
the circadian cycle to inhibit CLOCK/BMAL1 activity.
The PER components aid in nuclear localization of the
PER/CRY complex, while the CRY components appear
to function mainly as transcriptional repressors. Addi-
tional controls over this feedback loop include the
CCG product, casein kinase 13, which is involved in reg-
ulating the rates of PER and CRY degradation through
posttranslational modification. The cyclical nature of
BMAL1 expression in part drives the circadian oscilla-
tion and may be positively regulated by other CCGs,
RORA, and negatively regulated by Rev-erb-a. This sec-
ond interlocking loop is thought to maintain the precise
and robust nature of rhythms in mammals.
In a recent issue of Molecular Cell, Koeffler and col-
leagues (Gery et al., 2006) explored the relationship be-
tween PER1 expression and response of human cancer
cells to ionizing radiation (IR). They found that overex-
pression of PER1 sensitized cancer cells to IR-induced
apoptosis and that this phenotype was associated with
altered expression of key cell cycle regulators, including
MYC and p21. The MYC locus is a CCG whose expres-
sion is suppressed by the CLOCK/BMAL1 complex. The
finding that IR treatment induced PER1 expression and
nuclear localization suggested a mechanistic link be-
tween circadian cycling and cell growth control. Since
PER proteins play a role in inhibiting BMAL1 activity, it
was proposed that high levels of PER1 could result in
decreased activity of BMAL1, leading to derepression
of MYC and induction of apoptosis. In addition to its
influence over IR-induced apoptosis, PER1 was also
found to be involved in pathways that respond to DNA
damage, including the ATM kinase and downstream
effector, CHK2. These factors are activated by double-
strand breaks and are involved in initiating DNA repair
and cell cycle arrest or apoptosis. PER1 was found to
physically interact with and activate components of
the ATM pathway, suggesting that it also has a role in
the DNA damage response pathway that may be inde-
pendent of its role in clock function.
Perhaps the most intriguing aspect of the work by
Koeffler and colleagues is the relationship between
PER1 expression and cancer cell physiology. In one
avenue of experimentation, PER1 overexpression in
cancer cells lead to reduced colony formation and clo-
nogenic expansion. This observation was used as evi-
dence to support the idea that PER1 suppresses the
growth and transforming potential of cancer cells and
might act as a tumor suppressor. In a second avenue
of experimentation, PER1 expression was examined in
human tumors and it was found to be significantly
downregulated in lung and breast tumor tissue com-
pared to matched normal tissue. Taken together, these
results suggest that PER1 is a potential tumor suppres-
sor gene and its downregulation could play a role in
tumorigenesis.
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esting especially in light of the earlier observation that
mPer2 null mice are unusually cancer prone, developing
spontaneous salivary gland hyperplasia and teratomas
much sooner than their wild-type counterparts (Fu
et al., 2002). In wild-type mice, clock genes are upregu-
lated and Myc expression is repressed following g-radi-
ation. These responses fail in the mPer2 null mice,
leading to derepression of Myc and uncontrolled cell
growth and tumor formation. The combined findings
of PER1 overexpression inducing apoptosis and
mPer2 deficiency resulting in uncontrolled cell growth
are intriguing and suggest a tumor suppressor role for
the PER genes and support the idea that disruption of
a circadian factor may increase risk for carcinogenesis
(Figure 1).
Although the results of thePER experiments can be in-
terpreted in light of circadian biology, they are not defin-
itive proofs of such a link. In this regard, recent data in the
literature demonstrated that mice with a complete dis-
ruption of circadian rhythms do not display an increased
sensitivity to cancer. Using the Cry12/2Cry22/2 murine
model, cell cycle and DNA damage check-points, as
well as predisposition to spontaneous and IR-induced
cancers, were found to be no different than in wild-type
mice (Gauger and Sancar, 2005). These results have
lead Sancar and colleagues to support the view that dis-
ruption of circadian rhythm, in itself, is not sufficient to
sensitize cells to cancerous transformation. Rather, it
may be that individual clock components, such as the
PERs, play independent roles in other biological pro-
Figure 1. Clocks, Clock-Controlled Genes, and Cell Cycle Decisions
Altered expression of Period genes (Per2 deficiency or Per1 overex-
pression) appears to mediate cell fate decisions (cancer, apoptosis)
through regulation of the expression of various clock-controlled
genes involved in cell cycle regulation and DNA damage control.
Whether thePeriod genes, known core circadian clock components,
act through disruption of the circadian clock or through a clock-
independent mechanism (question marks) is still unclear.cesses, such as the cell cycle. That is, PER may act out-
side the framework of the circadian oscillator by mecha-
nisms that are yet to be determined.
The link between PER function and cell cycle control
and tumorigenesis is an intriguing one. Perhaps one of
the most important questions going forward is whether
it is circadian biology that is directly linked to cell divi-
sion and DNA damage control or whether it is individual
components of the clock that take on unique roles in
these biological processes. Arguing for a direct link be-
tween circadian clocks and cell cycle is the PER1 and
Per2 evidence cited above, as well as the observation
that Cry12/2Cry22/2 mice display reduced rates of
mitosis and lagging liver regeneration after partial hep-
atectomy (Matsuo et al., 2003). Arguing against the
importance of a link between circadian rhythms and
cell division is the unaltered sensitivity of Cry12/2
Cry22/2 null mice to spontaneous and IR-induced
cancer, as well as the observation that most circadian
mutants, including Bmal1(Mop3) and Clock mutants,
as well as Per1/Per2 and Cry1/Cry2 double mutants,
display apparently normal embryogenesis. Hopefully,
experimental evidence in the years to come will reveal
how clocks themselves, or the individual clock com-
ponents, are causally linked to proliferative diseases
such as cancer. A better understanding of the function
of clock proteins in the biology of cell division and
cancer could be an important first step in the develop-
ment of new strategies to prevent and treat human
malignancy.
Jacqueline A. Walisser1 and Christopher A. Bradfield1
1McArdle Laboratory for Cancer Research
University of Wisconsin
1400 University Ave
Madsion, Wisconsin, 53705
Selected Reading
Fu,L.,Pelicano,H.,Liu,J.,Huang,P.,andLee,C. (2002).Cell111, 41–50.
Gauger, M.A., and Sancar, A. (2005). Cancer Res. 65, 6828–6834.
Gorbacheva, V.Y., Kondratov, R.V., Zhang, R., Cherukuri, S.,
Gudkov, A.V., Takahashi, J.S., and Antoch, M.P. (2005). Proc. Natl.
Acad. Sci. USA 102, 3407–3412.
Hansen, J. (2001). Epidemiology 12, 74–77.
Gery, S., Komatsu, N., Baldjyan, L., Yu, A., Koo, D., and Koeffler,
H.P. (2006). Mol. Cell 22, 375–382.
Matsuo, T., Yamaguchi, S., Mitsui, S., Emi, A., Shimoda, F., and
Okamura, H. (2003). Science 302, 255–259.
Mormont, M.C., Waterhouse, J., Bleuzen, P., Giacchetti, S., Jami, A.,
Bogdan, A., Lellouch, J., Misset, J.L., Touitou, Y., and Levi, F. (2000).
Clin. Cancer Res. 6, 3038–3045.
